Importance Worldwide, the burden of heart failure has increased to an estimated 23 million
people, and approximately 50% of cases are HF with reduced ejection fraction (HFrEF) …

Heart failure is a global public health problem that affects more than 26 million people
worldwide. The global burden of heart failure is growing and is expected to increase …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

Background: Epidemiology of patients with worsening heart failure and reduced ejection
fraction (HFrEF) in the real-world setting is not well described. Objectives: The purpose of …

Heart failure is a complex clinical syndrome resulting from impairment of ventricular filling or
ejection of blood associated with symptoms of dyspnea, fatigue, and peripheral and/or …

The advent of newly available medical therapies for heart failure with reduced ejection
fraction (HFrEF) has resulted in many potential therapeutic combinations, increasing …

It is estimated that half of all patients with heart failure (HF) have HF with preserved ejection
fraction (HFpEF). Yet this form of HF remains a diagnostic and therapeutic challenge …

Importance In recent years, significant progress has been made in the pharmacologic
treatment of heart failure (HF) with reduced ejection fraction (HFrEF), but there is still …

Background: Guidelines strongly recommend patients with heart failure with reduced
ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical …

Heart failure (HF) is a clinical syndrome of diverse etiologies and can be associated with
preserved, reduced, or mid-range ejection fraction (EF). In the community, heart failure with …